ReviewDialogues in clinical neuroscience2020
The endocannabinoid system in modulating fear, anxiety, and stress .
Review in Dialogues in clinical neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Peripheral endocannabinoids in major depressive disorder and alcohol use disorder: a systematic review.BMC psychiatry · 2024Pooled it
- Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.European child & adolescent psychiatry · 2024Pooled it
- Review
- Sex-Specific Epigenetic Patterns in Endocannabinoid System Genes Following High-Altitude Exposure: An Exploratory Study.Brain sciences · 2026Article
- Differential Effects of Oleoyl Serine and HU-910 on Anxiety-like and Depression-like Behaviors in Male and Female WKY Rats.International journal of molecular sciences · 2026Article
- Endocannabinoid modulation of defensive state transitions to innate and learned threat.Psychopharmacology · 2026Article
- Endocannabinoid response to social stress in chronic non-medical prescription opioid users.Psychopharmacology · 2026Article
- Clinical Outcomes and Patient Profiles in the UK Medical Cannabis Registry: A k-Means Clustering Analysis.Journal of clinical pharmacology · 2026Article
- Long-term consequences of prenatal saccharin exposure: evidence of sex-specific molecular programing in the prefrontal cortex and behavior of adolescent rats.Frontiers in behavioral neuroscience · 2026Article
- Bridging reward and resilience: the endocannabinoid system as a unifying mechanism in exercise-induced protection against major depressive disorder.Frontiers in psychiatry · 2026Review
- Exercise-induced anandamide-CB1R signaling and prefrontal-amygdala stress circuits in adolescent depression: a critical hypothesis-driven narrative review.Frontiers in psychiatry · 2026Review
- Exploring the impact of chronic intermittent EU-GMP certified Cannabis sativa L. therapy and its relevance in a rat model of aging.Journal of cannabis research · 2025Article
- Psilocybin mitigates behavioral despair and cognitive impairment in treatment-resistant depression model using wistar kyoto rats.Scientific reports · 2025Article
- The Role of Long Non-Coding RNA in Anxiety Disorders: A Literature Review.International journal of molecular sciences · 2025Review
- Stress-induced changes in the molecular processes underlying fear memories: implications for PTSD and relevant animal models.Molecular psychiatry · 2025Review
- Impact of cannabinoids on cancer outcomes in patients receiving immune checkpoint inhibitor immunotherapy.Frontiers in immunology · 2025Review
- Dysregulated glycerophospholipid metabolism in amygdala may mediate favipiravir-induced anxiety-like behaviors in mice.Frontiers in pharmacology · 2025Article
- Investigating endocannabinoid system and subjective responses to exercise in cancer patients: Rationale and future research directions.JSAMS plus · 2024Review
- Cannabidiol Supplements in Romania: Bridging the Gap Between Marketed Claims and Clinical Reality.Pharmacy (Basel, Switzerland) · 2024Article
- Psychotomimetic compensation versus sensitization.Pharmacology research & perspectives · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The endocannabinoid system is widely expressed in the limbic system, prefrontal cortical areas, and brain structures regulating neuroendocrine stress responses, which explains the key role of this system in the control of emotions. In this review, we update recent advances on the function of the endocannabinoid system in determining the value of fear-evoking stimuli and promoting appropriate behavioral responses for stress resilience. We also review the alterations in the activity of the endocannabinoid system during fear, stress, and anxiety, and the pathophysiological role of each component of this system in the control of these protective emotional responses that also trigger pathological emotional disorders. In spite of all the evidence, we have not yet taken advantage of the therapeutic implications of this important role of the endocannabinoid system, and possible future strategies to improve the treatment of these emotional disorders are discussed. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.